Study design and setting
This prospective, randomized and double-blind clinical study was conducted at Hangzhou First People’s Hospital from Mar 2022 to Feb 2023. The study was approved by the Research Ethics Committee of Hangzhou First People’s Hospital (IIT-20220217-0021) and registered in the Chinese Clinical Trial Registry (ChiCTR2100050021). Written informed consent was obtained from all subjects participating in the trial.